Pharnext’s PLEODRUG™, PXT3003, to be Featured in Multiple Presentations at the 2017 Peripheral Nerve Society Meeting
June 27 2017 - 10:45AM
Business Wire
Status of ongoing pivotal Phase 3 trial for
PXT3003 to be presented in oral and poster sessions
Regulatory News:
Pharnext SA (FR00111911287 - ALPHA) (Paris:ALPHA),
a biopharmaceutical company pioneering a new approach to the
development of innovative drugs based on the combination and
repositioning of known drugs, today announced that the Company will
present an update from its ongoing pivotal Phase 3 clinical trial
evaluating lead PLEODRUG™ PXT3003, in development for the treatment
of Charcot-Marie-Tooth type 1A disease (CMT1A), in a poster and at
an oral session at the upcoming 2017 Peripheral Nerve Society
Meeting. Additional data related to PXT3003 and CMT1A will also be
featured in two posters at the meeting, which is being held on July
8-12 in Sitges, Spain.
- Clinical Trials Update sessions -
Tuesday July 11, 2017, 7:30am to 8:30am CEST
- Oral Presentation “Status of the
ongoing multi-center, randomised, double-blind, placebo controlled,
pivotal phase III study to assess the efficacy and safety of
PXT3003 for CMT1A (PLEO-CMT).” R. Goedkoop et al.
- Presenter: René Goedkoop, MD,
Chief Medical Officer, Pharnext, Issy-les-Moulineaux, France
- Poster Viewing Session #2 – Monday
July 10, 2017
- Poster P2_81 (abstract
34948) “Sensitivity to change of the Charcot-Marie-Tooth
Neuropathy Score (CMTNS) and Overall Neuropathy Limitation Scale
(ONLS) in a database of French patients with CMT1A.” J. Foucquier
et al.
- Poster Viewing Session #4 –
Wednesday July 12, 2017
- Poster P4_42 (abstract 34857)
“PXT3003, a fixed combination of baclofen, naltrexone and sorbitol,
for the treatment of Charcot-Marie-Tooth disease type 1A (CMT1A):
status of a multicenter, double-blind, placebo-controlled, pivotal
Phase III study (PLEOMCT).” S. Attarian et al.
- Poster P4_58 (abstract 34930)
“The combinational drug PXT3003 improves neuromuscular function in
an animal model of Charcot-Marie-Tooth type 1A disease.” T. Prukop
et al.
All abstracts will be published in the Journal of the Peripheral
Nervous System (JPNS) accessible at:
www.wileyonlinelibrary.com/journal/JPNS
About PharnextPharnext is an advanced clinical-stage
biopharmaceutical company founded by renowned scientists and
entrepreneurs including Professor Daniel Cohen, a pioneer in modern
genomics. Pharnext has two lead products in clinical development.
PXT3003 is currently in an international Phase 3 trial for the
treatment of Charcot-Marie-Tooth disease type 1A and benefits from
orphan drug status in Europe and the United States. PXT864 has
generated positive Phase 2 results in Alzheimer’s disease. Pharnext
is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The
Company identifies and develops synergic combinations of
repositioned drugs at new optimal lower doses. These PLEODRUG™
offer several key advantages: efficacy, safety and intellectual
property including several product or composition of matter patents
already granted. The Company is supported by a world-class
scientific team.
The company Pharnext is listed on Euronext Growth Stock Exchange
in Paris (ISIN code: FR00111911287).
For more information, visit www.pharnext.com
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170627005829/en/
PharnextXavier Paoli, +33 (0)1 41 09 22 30Chief
Commercial Officercontact@pharnext.comorPharnextPierre
Schwich, +33 (0)1 41 09 22 30Chief Financial
Officerinvestors@pharnext.comorInvestor Relations (Europe)MC
Services AGAnne Hennecke, +49 211 529252
22anne.hennecke@mc-services.euorInvestor Relations
(U.S.)Stern Investor Relations, Inc.Sarah McCabe, +1
212-362-1200sarah@sternir.comorFinancial Communication
(France)NewCapEmmanuel Huyn, +33 (0)1 44 71 20
40pharnext@newcap.euorMedia Relations (Europe)ALIZE
RPCaroline CarmagnolMargaux Pronost+33 (0)1 44 54 36
64pharnext@alizerp.comorMedia Relations (U.S.)Russo
PartnersTony RussoScott Santiamo+1 212-845-4251+1
718-344-5843tony.russo@russopartnersllc.comscott.Santiamo@russopartnersllc.com
Pharnext (EU:ALPHA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pharnext (EU:ALPHA)
Historical Stock Chart
From Apr 2023 to Apr 2024
